The Expanded Access Cure: A Twenty-First Century Framework for Companies
Through expanded access protocols, the Food and Drug Administration (FDA) allows patients with serious or immediately life-threatening diseases access to experimental drugs outside the clinical trial setting when no satisfactory alternative treatment is available. While the FDA has established a mec...
| Authors: | ; |
|---|---|
| Format: | Electronic Article |
| Language: | English |
| Check availability: | HBZ Gateway |
| Journals Online & Print: | Drawer...
|
| Fernleihe: | Fernleihe für die Fachinformationsdienste |
| Published: |
Springer
2019
|
| In: |
Journal of business ethics
Year: 2019, Volume: 156, Issue: 1, Pages: 155-171 |
| Further subjects: | B
Compassionate use
B FDA B Experimental drugs B Resource Allocation B Investigational drugs B Pharmaceutical manufacturers B Corporate frameworks B Expanded access |
| Online Access: |
Volltext (lizenzpflichtig) |
MARC
| LEADER | 00000caa a22000002 4500 | ||
|---|---|---|---|
| 001 | 1785668552 | ||
| 003 | DE-627 | ||
| 005 | 20230710121328.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 220112s2019 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1007/s10551-017-3533-3 |2 doi | |
| 035 | |a (DE-627)1785668552 | ||
| 035 | |a (DE-599)KXP1785668552 | ||
| 035 | |a (DE-He213)s10551-017-3533-3-e | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rda | ||
| 041 | |a eng | ||
| 084 | |a 1 |2 ssgn | ||
| 100 | 1 | |a Lee, Stacey B. |e VerfasserIn |4 aut | |
| 245 | 1 | 4 | |a The Expanded Access Cure: A Twenty-First Century Framework for Companies |
| 264 | 1 | |c 2019 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 520 | |a Through expanded access protocols, the Food and Drug Administration (FDA) allows patients with serious or immediately life-threatening diseases access to experimental drugs outside the clinical trial setting when no satisfactory alternative treatment is available. While the FDA has established a mechanism for providing patients with unapproved drug access, the regulations do not require the pharmaceutical company to provide the drug. The drug company’s permission to use its experimental drug is a necessary prerequisite to using the FDA’s expanded access mechanism. Increasingly, drug companies are coming under scrutiny regarding the programs governing that decision-making power. Historically, disclosing whether a company has an expanded access program, and whether or how it would respond to an expanded access request, has been left to discretion of the drug companies themselves. Few manufacturers publish adequate expanded access protocols. As a result, patients were provided with little insight into how companies evaluate expanded access requests and are naturally skeptical as to the ethical integrity of the process. The recently passed 21st Century Cures Act changes that practice by requiring drug companies to have, and make publically available, their expanded access procedures including criteria for evaluating and responding to patient requests. In this article, we contend that complying with the new transparency provisions will require drug companies to respond to several unresolved expanded access issues. Namely, how to reconcile a patient’s desire to access lifesaving experimental therapies alongside the company and society’s interest in the efficient development of new drugs. Even more challenging, how can companies devise practices for evaluating and processing expanded access requests that also fairly and equitably acknowledge those concerns? In addressing these questions, this article explores the legal, regulatory, business, and societal influences that have shaped expanded access policies and practices. From there, we provide companies a framework that balances appropriately the desires of individuals and gaining the requisite approvals ensure access not just for one person but for society. | ||
| 650 | 4 | |a Resource Allocation | |
| 650 | 4 | |a Pharmaceutical manufacturers | |
| 650 | 4 | |a FDA | |
| 650 | 4 | |a Investigational drugs | |
| 650 | 4 | |a Experimental drugs | |
| 650 | 4 | |a Corporate frameworks | |
| 650 | 4 | |a Compassionate use | |
| 650 | 4 | |a Expanded access | |
| 700 | 1 | |a Murata, Alexandra Y. |e VerfasserIn |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Journal of business ethics |d Dordrecht : Springer, 1982 |g 156(2019), 1, Seite 155-171 |h Online-Ressource |w (DE-627)270937129 |w (DE-600)1478688-6 |w (DE-576)121465284 |x 1573-0697 |7 nnns |
| 773 | 1 | 8 | |g volume:156 |g year:2019 |g number:1 |g pages:155-171 |
| 856 | 4 | 0 | |u https://doi.org/10.1007/s10551-017-3533-3 |x Resolving-System |z lizenzpflichtig |3 Volltext |
| 935 | |a mteo | ||
| 951 | |a AR | ||
| ELC | |a 1 | ||
| ITA | |a 1 |t 1 | ||
| LOK | |0 000 xxxxxcx a22 zn 4500 | ||
| LOK | |0 001 4033727450 | ||
| LOK | |0 003 DE-627 | ||
| LOK | |0 004 1785668552 | ||
| LOK | |0 005 20220112043920 | ||
| LOK | |0 008 220112||||||||||||||||ger||||||| | ||
| LOK | |0 035 |a (DE-Tue135)IxTheo#2021-12-30#93BA85683E8D367A9AEB7F02983BB1EFA7C9EAF2 | ||
| LOK | |0 040 |a DE-Tue135 |c DE-627 |d DE-Tue135 | ||
| LOK | |0 092 |o n | ||
| LOK | |0 852 |a DE-Tue135 | ||
| LOK | |0 852 1 |9 00 | ||
| LOK | |0 935 |a ixzs |a ixrk |a zota | ||
| ORI | |a SA-MARC-ixtheoa001.raw | ||